Why US Fertility Professionals Can Benefit from the Updated NICE Fertility Guidelines
At IVF Store, we share resources that help fertility professionals stay informed, think critically, and continue delivering the highest standard of care. That is why we wanted to highlight the newly updated NICE guideline, Fertility problems: assessment and treatment (NG257), published on 31 March 2026. For US embryologists, IVF labs, and fertility teams, it offers a valuable international perspective on how another major healthcare system reviews evidence, defines best practice, and decides which tests and treatments should or should not be used routinely. The guideline replaces CG156 and is intended to reduce variation in practice and improve how fertility problems are investigated and managed.
This is not about suggesting that UK guidance should replace US guidance. It is about giving US colleagues access to another serious, evidence-based framework that can broaden perspective, sharpen judgment, and support thoughtful decision-making. The guideline applies to people with a known clinical cause of infertility, those who have not achieved pregnancy after 12 months of regular unprotected sexual intercourse, and those who have not conceived after 6 cycles of artificial insemination. It also explicitly applies regardless of sexual orientation, partnership status, or gender identity when the clinical criteria are met.
Updated NICE Fertility Guidelines 2026: Why US Fertility Professionals Should Pay Attention
One of the clearest messages in the updated NICE guideline is that fertility care should be evidence-based, specialist-led, and clearly explained. NICE emphasizes informed decision-making using evidence-based information, recommends supporting verbal counseling with written or online information, highlights the psychological burden of fertility problems, and recommends counseling before, during, and after treatment. It also states that people with fertility problems should be treated by a specialist team because that improves effectiveness, efficiency, and satisfaction with care.
That is one reason this document feels relevant well beyond the UK. It is not simply a list of recommendations. It is a broad view of how a mature fertility system is organizing infertility investigation, treatment escalation, patient communication, and laboratory decision-making in a more consistent way. For embryologists and IVF labs, that wider context matters because lab decisions are never separate from the rest of the patient journey.
Fertility Assessment Guidelines: When NICE Recommends Investigation and Referral
The early fertility advice is practical and useful. NICE says that more than 80% of heterosexual couples in the general population will conceive within one year if the woman is under 40, contraception is not used, and intercourse is regular. Of those who do not conceive in the first year, about half will conceive in the second year. The guideline also reinforces that fertility declines with age, especially female fertility, and provides cumulative pregnancy estimates by age. For people trying to conceive through intercourse, NICE recommends intercourse every 2 to 3 days. For those using artificial insemination, it recommends timing insemination around ovulation.
When it comes to moving from trying to conceive to formal investigation, NICE keeps a clear structure. In the absence of a known cause, both partners should be offered further assessment after one year of unprotected vaginal intercourse. If conception is being attempted through artificial insemination, further assessment should be offered after 6 cycles if pregnancy has not occurred. Referral should happen earlier at presentation if the patient is 36 or older, or if either partner has a suspected or known clinical cause of infertility or a history of risk factors. One important 2026 clarification is that if miscarriage or ectopic pregnancy occurs during the waiting period, during expectant management for unexplained infertility, or during the 12 cycles of artificial insemination, the clock does not restart.
For busy fertility professionals, this section is especially helpful because it gives a simple framework for when to reassure, when to investigate, and when to move more quickly.
Lifestyle Factors That Affect Fertility: Alcohol, Smoking, BMI, Caffeine, and Medications
The lifestyle section is more current and practical than many brief summaries of fertility guidance. NICE advises that women trying to conceive should avoid intoxication and that the safest approach is to avoid alcohol altogether, while also noting that excessive alcohol intake is detrimental to semen quality. It reinforces smoking cessation, states there is no consistent evidence linking caffeinated beverages to fertility problems, and addresses both obesity and low body weight as clinically relevant. It also specifically says clinicians should ask about prescription drugs, over-the-counter products, and recreational drugs, including GLP-1 agonists, testosterone-replacement therapy, finasteride, NSAIDs, lubricants, anabolic steroids, and cannabis, and provide advice on their potential impact on fertility or pregnancy.
That last point is especially relevant now. In day-to-day practice, medication exposure and metabolic health are becoming a much larger part of fertility conversations. NICE makes clear that these are not side notes. They belong in the main workup and in early counseling.
Male Factor Infertility Guidelines: Semen Analysis, Sperm DNA Fragmentation, and Genetic Testing
For male factor infertility, the updated guideline becomes very specific. NICE continues to anchor semen analysis to WHO reference values, including semen volume of at least 1.4 ml, sperm concentration of at least 16 million/ml, total motility of at least 42 percent, progressive motility of at least 30 percent, vitality of at least 54 percent, and morphology of at least 4 percent normal forms. If the first semen analysis is abnormal, a repeat confirmatory test is recommended, ideally after 3 months unless azoospermia or severe oligozoospermia is present. After 2 or more abnormal semen analyses, NICE recommends physical examination of the scrotum and testes and consideration of serum testosterone and gonadotrophin levels.
One of the clearest and most talked-about takeaways for many clinics will be NICE’s position on sperm DNA fragmentation. The guideline explicitly says not to carry out sperm DNA integrity testing. It also says not to offer supplements, antioxidants, or medical treatments to improve sperm DNA integrity, and not to offer surgical sperm retrieval as a way to improve outcomes in non-azoospermic men with elevated fragmentation levels. That is a strong signal against routine use of this pathway in standard fertility care.
At the same time, NICE strengthens specific genetic pathways in severe male factor infertility. It recommends Y chromosome microdeletion testing in idiopathic azoospermia or sperm concentration under 1 million/ml, CFTR mutation testing in idiopathic suspected obstructive azoospermia or vasal abnormality, karyotype testing in idiopathic azoospermia, and consideration of karyotype testing if sperm concentration remains under 5 million/ml. It also recommends genetic counseling when a specific genetic defect associated with male factor infertility is identified.
For andrology teams, this section offers a more disciplined framework: less routine use of weakly supported testing, but more precision where genetics truly matter.
Male Infertility Treatment Recommendations: Azoospermia, micro-TESE, and Varicocele
In treatment, NICE supports gonadotrophin therapy for hypogonadotropic hypogonadism and advises against androgens for semen abnormalities. It allows surgical correction or surgical sperm retrieval for obstructive azoospermia, recommends surgical sperm retrieval for non-obstructive azoospermia, and says micro-TESE can be considered. It also says surgical sperm retrieval should not be offered in the presence of Y chromosome AZFa or AZFb microdeletions. Varicocele treatment can be considered when clinically detected and associated with reduced semen parameters in a couple trying to conceive spontaneously.
This is one of the more useful sections in the guideline because it separates intervention that appears justified from intervention that may sound appealing but is not strongly supported. For clinics trying to keep treatment pathways both effective and responsible, that distinction matters.
Female Factor Infertility Guidelines: Ovulation Testing, Ovarian Reserve, and Tubal Assessment
On the female-factor side, NICE continues moving away from older or lower-value tests. It says post-coital testing of cervical mucus should not be used routinely because it has no predictive value for pregnancy rate. It says maternal age should be used as an initial predictor of pregnancy chances, and that AMH should not be used to predict spontaneous conception. However, AMH or antral follicle count can be used to predict ovarian response and support counseling about the likelihood of live birth following assisted conception. It also states that FSH should not be used as a predictor of ovarian response or assisted conception outcome.
The female diagnostic pathway itself is practical, but the wording is important. NICE says regular monthly cycles make ovulation likely, yet still recommends mid-luteal progesterone testing to confirm ovulation during infertility investigation. Basal body temperature charts should not be used. Prolactin testing should not be routine and should be limited to people with ovulatory disorder, galactorrhoea, or a pituitary tumour. Thyroid testing should only be offered when symptoms suggest thyroid disease. For tubal assessment, HSG is recommended for patients without known comorbidities, hysterosalpingo-contrast ultrasonography may be considered where expertise exists, and laparoscopy with dye should be used when comorbidities such as endometriosis, previous ectopic pregnancy, or pelvic inflammatory disease are suspected. Hysteroscopy should not be offered unless a uterine or endometrial abnormality is clinically suspected.
For patient counseling, this section is very useful because it helps separate what is genuinely informative from what has traditionally been done without adding much value.
Additional Fertility Testing Recommendations: Viral Screening, Rubella, Chlamydia, and Coeliac Disease
There are also several practical additions that many readers will appreciate. NICE recommends HIV, hepatitis B, and hepatitis C testing for people undergoing IVF. It recommends rubella testing when vaccination status is uncertain and vaccination for those who are susceptible, with advice not to become pregnant for at least one month afterward. Before uterine instrumentation, it recommends screening for Chlamydia trachomatis or considering prophylactic antibiotics if screening has not been performed. It also says serological testing for coeliac disease should be considered in unexplained subfertility.
These are not the headline-grabbing parts of the update, but they matter. They affect safety, timing, readiness for treatment, and how smoothly clinics move from investigation into care.
Unexplained Infertility Guidelines: Expectant Management, Ovarian Stimulation, and IUI
For unexplained infertility, the updated pathway is more structured than many readers may expect. NICE advises people with unexplained fertility problems who are having regular unprotected intercourse to keep trying for a total of 2 years before treatment. It specifically says not to offer ovarian stimulation as a stand-alone treatment. After 2 years, treatment options should be discussed, and before IVF, clinicians may consider up to 4 cycles of IUI with ovarian stimulation using gonadotrophins, or offer IVF directly.
This is a good example of the overall tone of the guideline. NICE is trying to reduce low-value intervention while still leaving room for thoughtful, stepwise care before IVF when that makes sense.
IUI Guidelines 2026: When NICE Recommends Intrauterine Insemination Before IVF
The guideline also preserves a defined role for IUI. NICE recommends 12 cycles of unstimulated IUI before IVF for people who are unable to have vaginal intercourse or would find it very difficult because of physical disability or psychosexual problems, and for couples who require donor sperm because azoospermia cannot be managed with suitable sperm retrieval. For those using donor insemination who have not conceived after 6 cycles and have no suspected cause of infertility, NICE recommends 6 cycles of unstimulated donor IUI before considering IVF. It also states that donor sperm IUI should be used in preference to intracervical insemination because it improves pregnancy rates.
For clinics that use IUI selectively, this section helps clarify where NICE still sees clear value and where it does not.
IVF Access Guidelines: Who Qualifies for IVF and How NICE Defines a Full IVF Cycle
The IVF access section is one of the most important parts of the update. NICE says IVF should be discussed in line with the HFEA Code of Practice and with ovarian reserve taken into account. It recommends IVF for people who have not yet reached their 42nd birthday if there is a diagnosed cause of infertility for which other treatments are not suitable or have not been successful, if there is unexplained infertility after 2 years of regular unprotected intercourse with or without IUI, or if pregnancy has not occurred after 12 cycles of artificial insemination, where 6 or more cycles were IUI.
NICE defines a full cycle as one episode of ovarian stimulation plus transfer of any resulting fresh and frozen embryos. For those under 40 who meet the criteria, NICE recommends an initial 3 full cycles, with consideration of up to 3 further full cycles if pregnancy has not occurred. For those aged 40 to 41 who meet criteria and have not had IVF before, it recommends 1 full cycle.
Even though US systems differ, this section is still valuable because it shows how another evidence-review body thinks about access, sequencing, and when IVF becomes the appropriate next step.
IVF Add-Ons Guidelines: Endometrial Scratch, Hysteroscopy, Endometrial Receptivity Testing, and Immunological Treatments
In the IVF procedures section, NICE is notably cautious about add-ons. It says not to offer endometrial scratch as a pre-treatment to improve IVF outcomes, not to offer hysteroscopy as a pre-treatment to improve IVF outcomes unless uterine or endometrial abnormalities are suspected, and not to offer endometrial receptivity testing as an embryo-transfer add-on. It also states that immunological agents, including intralipids, intravenous immunoglobulins, and steroids, should not be used as part of fertility treatment. This is one of the clearest themes of the document: where evidence is weak, NICE prefers restraint.
For many US readers, this may be one of the most useful parts of the whole guideline because it directly addresses interventions that often come with a great deal of interest, a great deal of marketing, and not always enough supporting evidence.
Embryo Selection and Embryo Transfer Guidelines: PGT-A, Assisted Hatching, Single Embryo Transfer, and Ultrasound Guidance
The embryo selection and embryo transfer sections contain several practical recommendations that will be especially relevant to embryologists. NICE says not to offer PGT-A as part of fertility treatment to improve live birth rates. It says not to offer assisted hatching, but it does recommend ultrasound-guided embryo transfer because it improves pregnancy rates. It also says embryo quality at both cleavage and blastocyst stages should be evaluated using the ARCS and UK NEQAS embryo grading scheme.
Where a top-quality blastocyst is available, single embryo transfer should be used, and NICE gives age-based recommendations that continue to prioritize single embryo transfer in many early cycles, especially in younger patients or when top-quality embryos are available. It also says no more than 2 embryos should be transferred in any 1 cycle.
For IVF labs, this section is especially important because it ties embryo grading, embryo selection, and transfer decisions back to real outcomes, including live birth and multiple pregnancy risk.
ICSI Guidelines: When NICE Recommends ICSI and When It Should Not Be Used Routinely
ICSI remains important in the guideline, but the framing is selective rather than automatic. NICE says to offer ICSI when using surgically retrieved sperm or frozen-thawed oocytes. It says ICSI should be considered when semen parameters are abnormal, taking severity into account, or when a previous IVF cycle resulted in failed fertilization or a very low fertilization rate. At the same time, it says not to use ICSI for non-male factor fertility problems if semen parameters are normal. It also says not to use IMSI as an adjunct to ICSI and not to use PICSI in preference to standard ICSI. For embryologists and IVF labs, this is an important message: use ICSI when it is clinically justified, but do not let it become a default for every case.
This is very much in line with the overall direction of the guideline: use technology thoughtfully, not reflexively.
What the Updated NICE Fertility Guidelines Mean for US Embryologists, IVF Labs, and Fertility Clinics
Taken together, the 2026 NICE update is a strong statement in favor of specialist-led, evidence-based fertility care, with clearer thresholds for assessment, tighter recommendations around male-factor genetics and ovarian reserve interpretation, a more disciplined approach to IUI and IVF timing, and a distinctly cautious stance on add-ons that have not shown clear benefit. For US fertility professionals, the value of this guideline is not that every recommendation will map perfectly onto US reimbursement, regulation, or society guidance. The value is that it gives a very complete picture of how another mature fertility system is sorting high-value from low-value care.
That is exactly why IVF Store wanted to share it. It is a useful resource for embryologists, lab directors, fertility clinicians, and andrology teams who want a clearer, evidence-based summary of where practice is moving and how international guidance is evolving. In a field where patients depend on good judgment just as much as technology, that broader perspective is well worth having.
Read the Full NICE Fertility Problems Assessment and Treatment Guideline
For those who want to explore the full source, the guideline is Fertility problems: assessment and treatment (NG257), published 31 March 2026.
